Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change. At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol. The mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data. The main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.

NCT Number	NCT05733702
Lead Sponsor	Luxembourg Institute of Health Collaborators: Luxembourg National Research Fund, Centre Hospitalier du Luxembourg, Hôpitaux Robert Schuman, University of Luxembourg
Conditions	Inflammatory Bowel Diseases
Enrollment	100 participants
Start Date	2024-02-01
Primary Completion	2029-11 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2025-09-22